Creative Biogene has launched vesicular stomatitis virus (VSV) services in order to accelerate VSV-based studies...
Our promise to you:
Guaranteed product quality, expert customer support.
Creative Biogene has launched vesicular stomatitis virus (VSV) services in order to accelerate VSV-based studies in the area of cancer therapy, neuronal tracing and so on.
Vesicular stomatitis virus (VSV) is a prototypic non-segmented, negative-strand RNA virus in the genus of Vesiculovirus of the family Rhabdoviridae. The VSV genome is comprised of approximately 11,000 nucleotides which encodes five major viral proteins including G protein (G), large protein (L), phosphoprotein (P), matrix protein (M) and nucleoprotein (N).
Figure 1. Vesicular stomatitis virus (VSV)
VSV can infect a wide range of host cells and its lifecycle occurs in the cytoplasm of host cells. However, replication of VSV is limited to cells that are impaired in their interferon (IFN) pathways, and IFN in most cancer cells are believed to be impaired. This feature allows VSV to preferentially replicate in cancer cells and further destroy them. Results from preclinical studies have also demonstrated that VSV is a promising candidate in oncolytic virus (OV) therapy. Another wide use of VSV is tracing neuronal connections in vivo to elucidate the mechanisms of nervous system in information processing.
VSV Design & Production
There are several advantages that make VSV a powerful tool in scientific research and clinical therapy, including well-characterized biology, small and easily manipulated genome, inherent tumor specificity, rapid replication, not pathogenic to humans etc. Creative Biogene has established an efficient VSV platform for creating recombinant VSVs based on our experienced staffs and our advanced molecular biology techniques especially reverse genetics tools. So far, our VSV platform has successfully engineered various recombinant VSVs for use in anticancer and neural tracing studies. Scientists at Creative Biogene are happy to satisfy your needs in VSV design and production.
Figure 2. Green fluorescent image of cells infected with VSV-GFP.
Our Service Includes
Figure 3. Service workflow